165 related articles for article (PubMed ID: 36933062)
1. Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer.
Simigdala N; Chalari A; Sklirou AD; Chavdoula E; Papafotiou G; Melissa P; Kafalidou A; Paschalidis N; Pateras IS; Athanasiadis E; Konstantopoulos D; Trougakos IP; Klinakis A
Cell Mol Life Sci; 2023 Mar; 80(4):100. PubMed ID: 36933062
[TBL] [Abstract][Full Text] [Related]
2.
Cho SJ; Yoon C; Lee JH; Chang KK; Lin JX; Kim YH; Kook MC; Aksoy BA; Park DJ; Ashktorab H; Smoot DT; Schultz N; Yoon SS
Clin Cancer Res; 2018 Dec; 24(24):6556-6569. PubMed ID: 30108106
[TBL] [Abstract][Full Text] [Related]
3. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
[TBL] [Abstract][Full Text] [Related]
4. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Gala K; Li Q; Sinha A; Razavi P; Dorso M; Sanchez-Vega F; Chung YR; Hendrickson R; Hsieh JJ; Berger M; Schultz N; Pastore A; Abdel-Wahab O; Chandarlapaty S
Oncogene; 2018 Aug; 37(34):4692-4710. PubMed ID: 29755131
[TBL] [Abstract][Full Text] [Related]
5. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
[TBL] [Abstract][Full Text] [Related]
6. KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract][Full Text] [Related]
7. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.
Morel AP; Hinkal GW; Thomas C; Fauvet F; Courtois-Cox S; Wierinckx A; Devouassoux-Shisheboran M; Treilleux I; Tissier A; Gras B; Pourchet J; Puisieux I; Browne GJ; Spicer DB; Lachuer J; Ansieau S; Puisieux A
PLoS Genet; 2012; 8(5):e1002723. PubMed ID: 22654675
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene.
Phua YW; Nguyen A; Roden DL; Elsworth B; Deng N; Nikolic I; Yang J; Mcfarland A; Russell R; Kaplan W; Cowley MJ; Nair R; Zotenko E; O'Toole S; Tan SX; James DE; Clark SJ; Kouros-Mehr H; Swarbrick A
Breast Cancer Res; 2015 Jun; 17(1):83. PubMed ID: 26070602
[TBL] [Abstract][Full Text] [Related]
9. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.
Chakrabarti R; Hwang J; Andres Blanco M; Wei Y; Lukačišin M; Romano RA; Smalley K; Liu S; Yang Q; Ibrahim T; Mercatali L; Amadori D; Haffty BG; Sinha S; Kang Y
Nat Cell Biol; 2012 Nov; 14(11):1212-22. PubMed ID: 23086238
[TBL] [Abstract][Full Text] [Related]
10. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
Xi C; Hu Y; Buckhaults P; Moskophidis D; Mivechi NF
J Biol Chem; 2012 Oct; 287(42):35646-35657. PubMed ID: 22847003
[TBL] [Abstract][Full Text] [Related]
11. ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.
Khan IA; Yoo BH; Masson O; Baron S; Corkery D; Dellaire G; Attardi LD; Rosen KV
Oncogene; 2016 Nov; 35(44):5759-5769. PubMed ID: 27109096
[TBL] [Abstract][Full Text] [Related]
12. H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma.
Bosgana P; Nikou S; Dimitrakopoulos FI; Logotheti S; Tzelepi V; Kalophonos C; Bravou V; Kourea E; Sampsonas F; Zolota V
Curr Mol Pharmacol; 2021; 14(6):1028-1036. PubMed ID: 32867667
[TBL] [Abstract][Full Text] [Related]
13. The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.
Rampias T; Karagiannis D; Avgeris M; Polyzos A; Kokkalis A; Kanaki Z; Kousidou E; Tzetis M; Kanavakis E; Stravodimos K; Manola KN; Pantelias GE; Scorilas A; Klinakis A
EMBO Rep; 2019 Mar; 20(3):. PubMed ID: 30665945
[TBL] [Abstract][Full Text] [Related]
14. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
15. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.
Okada T; Sinha S; Esposito I; Schiavon G; López-Lago MA; Su W; Pratilas CA; Abele C; Hernandez JM; Ohara M; Okada M; Viale A; Heguy A; Socci ND; Sapino A; Seshan VE; Long S; Inghirami G; Rosen N; Giancotti FG
Nat Cell Biol; 2015 Jan; 17(1):81-94. PubMed ID: 25531777
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Van Keymeulen A; Lee MY; Ousset M; Brohée S; Rorive S; Giraddi RR; Wuidart A; Bouvencourt G; Dubois C; Salmon I; Sotiriou C; Phillips WA; Blanpain C
Nature; 2015 Sep; 525(7567):119-23. PubMed ID: 26266985
[TBL] [Abstract][Full Text] [Related]
17. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
18. Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract][Full Text] [Related]
19. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
20. The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis.
Ahmed S; Pryce BR; Al-Zahrani KN; Sabourin LA
Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt A):1590-1597. PubMed ID: 30327200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
